The CD30-targeted antibody–drug conjugate, BV, has undergone extensive preclinical and clinical evaluation, has been approved by multiple regulatory agencies, including both the FDA and the EMA, for the treatment of Hodgkin Lymphoma, ALCL and CD30 positive cutaneous T-cell lymphoma and is currently in use in 40 clinical trials for children and teenagers as listed in ClinicalTrials.gov (https://www.clinicaltrials.gov/ct2/results?term=brentuximab&Search=Apply&age_v=&age=0&gndr=&type=&rslt=).29–31 The present study was designed to examine the in vivo efficacy of BV against eIMS xenografts. This evidence concerns the gene TNFRSF8 and primary cutaneous T-cell non-Hodgkin lymphoma.